Skip to main content

Articles

Page 1 of 44

  1. Stress-induced hyperglycaemia at time of hospital admission has been linked to worse prognosis following acute myocardial infarction (AMI). In addition to glucose, other glucose-related indices, such as HbA1c,...

    Authors: Ching-Hui Sia, Mervyn Huan-Hao Chan, Huili Zheng, Junsuk Ko, Andrew Fu-Wah Ho, Jun Chong, David Foo, Ling-Li Foo, Patrick Zhan-Yun Lim, Boon Wah Liew, Ping Chai, Tiong-Cheng Yeo, Huay-Cheem Tan, Terrance Chua, Mark Yan-Yee Chan, Jack Wei Chieh Tan…

    Citation: Cardiovascular Diabetology 2021 20:211

    Content type: Original investigation

    Published on:

  2. Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the ...

    Authors: Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito and Dario Giugliano

    Citation: Cardiovascular Diabetology 2021 20:210

    Content type: Review

    Published on:

  3. The combination of diabetes mellitus (DM) and chronic kidney disease (CKD) is associated with a high risk of mortality. Annual assessment of the estimated glomerular filtration rate (eGFR) is recommended for p...

    Authors: Yu-Shan Chang, Yu-Hsuan Li and I-Te Lee

    Citation: Cardiovascular Diabetology 2021 20:209

    Content type: Original investigation

    Published on:

  4. Advanced glycation end-products, indicated by skin autofluorescence (SAF) levels, could be prognostic predictors of all-cause and cardiovascular mortality in patients with diabetes mellitus (DM) and renal dise...

    Authors: Mitsuhiro Kunimoto, Miho Yokoyama, Kazunori Shimada, Tomomi Matsubara, Tatsuro Aikawa, Shohei Ouchi, Kosuke Fukao, Tetsuro Miyazaki, Kei Fujiwara, Abidan Abulimiti, Akio Honzawa, Akie Shimada, Taira Yamamoto, Atsushi Amano, Masakazu Saitoh, Tomoyuki Morisawa…

    Citation: Cardiovascular Diabetology 2021 20:208

    Content type: Original investigation

    Published on:

  5. Previous studies suggested an adverse association between higher fasting blood glucose (FBG) variability and cardiovascular disease (CVD). Lifetime risk provides an absolute risk assessment during the remainde...

    Authors: Jianing Bi, Lulu Song, Lulin Wang, Mingyang Wu, Shouhua Chen, Youjie Wang, Shouling Wu and Yaohua Tian

    Citation: Cardiovascular Diabetology 2021 20:207

    Content type: Original investigation

    Published on:

  6. Insulin resistance (IR) is a known risk factor for cardiovascular disease (CVD) in non-diabetic patients through the association of hyperglycemia or associated metabolic factors. The triglyceride glucose (TyG)...

    Authors: Ya-Wen Lu, Chun-Chin Chang, Ruey-Hsing Chou, Yi-Lin Tsai, Li-Kuo Liu, Liang-Kung Chen, Po-Hsun Huang and Shing-Jong Lin

    Citation: Cardiovascular Diabetology 2021 20:206

    Content type: Original investigation

    Published on:

  7. Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications ca...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Giuseppe Bellastella and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:205

    Content type: Commentary

    Published on:

  8. With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapa...

    Authors: Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong and Huang-Tz Ou

    Citation: Cardiovascular Diabetology 2021 20:204

    Content type: Original investigation

    Published on:

  9. To assess the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) for type 2 diabetes on kidney outcomes stratified by patient baseline estimated glomerular filtration rate (eGFR) levels (i.e., eGFR...

    Authors: Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang and Huang-Tz Ou

    Citation: Cardiovascular Diabetology 2021 20:203

    Content type: Original investigation

    Published on:

  10. Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistanc...

    Authors: Alexander Zabala, Vladimer Darsalia, Marcus Lind, Ann-Marie Svensson, Stefan Franzén, Björn Eliasson, Cesare Patrone, Magnus Jonsson and Thomas Nyström

    Citation: Cardiovascular Diabetology 2021 20:202

    Content type: Original investigation

    Published on:

  11. Previous studies reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). Still, the predictive utility of the AIP is un...

    Authors: Liyao Fu, Ying Zhou, Jiaxing Sun, Zhaowei Zhu, Zhenhua Xing, Shenghua Zhou, Yongjun Wang and Shi Tai

    Citation: Cardiovascular Diabetology 2021 20:201

    Content type: Original investigation

    Published on:

  12. Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ve...

    Authors: Bradley Sarak, Subodh Verma, C. David Mazer, Hwee Teoh, Adrian Quan, Richard E. Gilbert, Shaun G. Goodman, Karan Bami, Otávio R. Coelho-Filho, Vineeta Ahooja, Djeven P. Deva, Vinay Garg, Sumeet Gandhi, Kim A. Connelly and Andrew T. Yan

    Citation: Cardiovascular Diabetology 2021 20:200

    Content type: Original investigation

    Published on:

  13. Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from gluco...

    Authors: Zhaoyang Hu, Feng Ju, Lei Du and Geoffrey W. Abbott

    Citation: Cardiovascular Diabetology 2021 20:199

    Content type: Original investigation

    Published on:

  14. Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to n...

    Authors: Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný and Guntram Schernthaner

    Citation: Cardiovascular Diabetology 2021 20:198

    Content type: Commentary

    Published on:

  15. Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/...

    Authors: Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur and Jae Hyeon Kim

    Citation: Cardiovascular Diabetology 2021 20:197

    Content type: Original investigation

    Published on:

  16. The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular protection prompted a ...

    Authors: Andrea Natali, Lorenzo Nesti, Domenico Tricò and Ele Ferrannini

    Citation: Cardiovascular Diabetology 2021 20:196

    Content type: Review

    Published on:

  17. The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large p...

    Authors: Matti A. Vuori, Jaakko Reinikainen, Stefan Söderberg, Ellinor Bergdahl, Pekka Jousilahti, Hugh Tunstall-Pedoe, Tanja Zeller, Dirk Westermann, Susana Sans, Allan Linneberg, Licia Iacoviello, Simona Costanzo, Veikko Salomaa, Stefan Blankenberg, Kari Kuulasmaa and Teemu J. Niiranen

    Citation: Cardiovascular Diabetology 2021 20:195

    Content type: Original investigation

    Published on:

  18. The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the e...

    Authors: Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha and Hertzel C. Gerstein

    Citation: Cardiovascular Diabetology 2021 20:194

    Content type: Original investigation

    Published on:

  19. Liver stiffness measurement (LSM, which reflects fibrosis) and controlled attenuation parameter (CAP, which reflects steatosis), two parameters derived from hepatic transient elastography (TE), have scarcely b...

    Authors: Claudia R. L. Cardoso, Cristiane A. Villela-Nogueira, Nathalie C. Leite and Gil F. Salles

    Citation: Cardiovascular Diabetology 2021 20:193

    Content type: Original investigation

    Published on:

  20. The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella…

    Citation: Cardiovascular Diabetology 2021 20:192

    Content type: Original investigation

    Published on:

  21. A prothrombotic state is a typical feature of type 2 diabetes mellitus (T2DM). Apart from increased platelet reactivity, endothelial dysfunction, hyperfibrinogenemia, and hypofibrinolysis are observed in T2DM....

    Authors: Agata Hanna Bryk-Wiązania and Anetta Undas

    Citation: Cardiovascular Diabetology 2021 20:191

    Content type: Review

    Published on:

  22. Insulin resistance (IR), evaluation of which is difficult and complex, is closely associated with cardiovascular disease. Recently, various IR surrogates have been proposed and proved to be highly correlated w...

    Authors: Qi Zhao, Yu-Jing Cheng, Ying-Kai Xu, Zi-Wei Zhao, Chi Liu, Tie-Nan Sun and Yu-Jie Zhou

    Citation: Cardiovascular Diabetology 2021 20:190

    Content type: Original investigation

    Published on:

  23. A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes melli...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:189

    Content type: Original investigation

    Published on:

  24. Apolipoprotein (Apo) A1 and Apo B are strongly associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the relationship between the Apo B/A1 ratio and the morphology of coronary vu...

    Authors: Fuxue Deng, Danni Li, Lei Lei, Qiang Yang, Qing Li, Hongtao Wang, Jie Deng, Qiangsun Zheng and Wei Jiang

    Citation: Cardiovascular Diabetology 2021 20:188

    Content type: Original investigation

    Published on:

  25. Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study.

    Authors: João Pedro Ferreira, Patrick Rossignol, George Bakris, Cyrus Mehta, William B. White and Faiez Zannad

    Citation: Cardiovascular Diabetology 2021 20:187

    Content type: Original investigation

    Published on:

  26. Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT...

    Authors: Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Kaoru Dohi, Kazuki Shiina, Takahisa Yamada, Keisuke Kida, Kazuo Eguchi, Hiroki Teragawa, Yasuchika Takeishi, Nobuyuki Ohte, Hirotsugu Yamada, Masataka Sata and Koichi Node

    Citation: Cardiovascular Diabetology 2021 20:186

    Content type: Original investigation

    Published on:

  27. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with sex-specific pathophysiology. Estrogen deficiency is believed to be responsible for the development of HFpEF in women. Ho...

    Authors: Ke Shi, Meng-Xi Yang, Shan Huang, Wei-Feng Yan, Wen-Lei Qian, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang

    Citation: Cardiovascular Diabetology 2021 20:185

    Content type: Original investigation

    Published on:

  28. Authors: Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex

    Citation: Cardiovascular Diabetology 2021 20:184

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2021 20:114

  29. Insulin resistance is associated with the incidence of diabetes and cardiovascular diseases such as myocardial infarction. The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) (TG/HD...

    Authors: Joungyoun Kim, Sang-Jun Shin, Ye-Seul Kim and Hee-Taik Kang

    Citation: Cardiovascular Diabetology 2021 20:183

    Content type: Original investigation

    Published on:

  30. Basement membrane (BM) accumulation is a hallmark of micro-vessel disease in diabetes mellitus (DM). We previously reported marked upregulation of BM components in internal thoracic arteries (ITAs) from type 2...

    Authors: Lasse Bach Steffensen, Xenia Emilie Sinding Iversen, Rasmus Søgaard Hansen, Pia Søndergaard Jensen, Anne-Sofie Faarvang Thorsen, Jes Sanddal Lindholt, Lars Peter Schødt Riber, Hans Christian Beck and Lars Melholt Rasmussen

    Citation: Cardiovascular Diabetology 2021 20:182

    Content type: Original investigation

    Published on:

  31. Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome tria...

    Authors: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk and Jan Westerink

    Citation: Cardiovascular Diabetology 2021 20:181

    Content type: Original investigation

    Published on:

  32. Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM....

    Authors: Se Yong Jang, Jieun Jang, Dong Heon Yang, Hyun-Jai Cho, Soo Lim, Eun-Seok Jeon, Sang Eun Lee, Jae-Joong Kim, Seok-Min Kang, Sang Hong Baek, Myeong-Chan Cho, Dong-Ju Choi, Byung-Su Yoo, Kye Hun Kim, Sue K. Park and Hae-Young Lee

    Citation: Cardiovascular Diabetology 2021 20:180

    Content type: Original investigation

    Published on:

  33. Type 2 diabetes mellitus is common in patients undergoing dialysis. However, the association between anti-diabetic drug use and survival outcomes is rarely discussed. We aimed to investigate whether continued ...

    Authors: Shih-Hsiang Ou, Hsin-Yu Chen, Nai-Wen Fang, Chun-Hao Yin, Chien-Liang Chen and Jin-Shuen Chen

    Citation: Cardiovascular Diabetology 2021 20:179

    Content type: Original investigation

    Published on:

  34. Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

    Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder

    Citation: Cardiovascular Diabetology 2021 20:178

    Content type: Original investigation

    Published on:

  35. It remains uncertain if prior use of oral anticoagulants (OACs) in COVID-19 outpatients with multimorbidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30-days afte...

    Authors: José Miguel Rivera-Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio-Eynullayeva, Paula Underhill, Francisco Marín and Gregory Y. H. Lip

    Citation: Cardiovascular Diabetology 2021 20:176

    Content type: Original investigation

    Published on:

  36. Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend cons...

    Authors: Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata and Koichi Node

    Citation: Cardiovascular Diabetology 2021 20:175

    Content type: Original investigation

    Published on:

  37. Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we com...

    Authors: Momoko Oe, Kazuya Fujihara, Mayuko Harada-Yamada, Taeko Osawa, Masaru Kitazawa, Yasuhiro Matsubayashi, Takaaki Sato, Yuta Yaguchi, Midori Iwanaga, Hiroyasu Seida, Takaho Yamada and Hirohito Sone

    Citation: Cardiovascular Diabetology 2021 20:174

    Content type: Original investigation

    Published on:

  38. There is a high incidence of cardiovascular disease in diabetes. Weight variability has been reported as independent risk factor for cardiovascular disease in the general population and preliminarily also in p...

    Authors: Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, Björn Eliasson, Stefan Franzén, Ann-Marie Svensson and Antonio Nicolucci

    Citation: Cardiovascular Diabetology 2021 20:173

    Content type: Original investigation

    Published on:

  39. Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathie...

    Authors: Etheresia Pretorius, Mare Vlok, Chantelle Venter, Johannes A. Bezuidenhout, Gert Jacobus Laubscher, Janami Steenkamp and Douglas B. Kell

    Citation: Cardiovascular Diabetology 2021 20:172

    Content type: Original investigation

    Published on:

  40. Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicti...

    Authors: Marco Witkowski, Yuping Wu, Stanley L. Hazen and W. H. Wilson Tang

    Citation: Cardiovascular Diabetology 2021 20:171

    Content type: Original investigation

    Published on:

  41. Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. Ho...

    Authors: Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod and Ofri Mosenzon

    Citation: Cardiovascular Diabetology 2021 20:169

    Content type: Original investigation

    Published on:

  42. Compared to individuals without type 2 diabetes mellitus, the relative increase in cardiovascular mortality is much higher in women than in men in individuals with type 2 diabetes mellitus.

    Authors: Marcello Ricardo Paulista Markus, Till Ittermann, Sabine Schipf, Martin Bahls, Matthias Nauck, Henry Völzke, Raul Dias Santos, Annette Peters, Tanja Zeller, Stephan Burkhard Felix, Ramachandran S. Vasan, Barbara Thorand, Elisabeth Steinhagen-Thiessen and Marcus Dörr

    Citation: Cardiovascular Diabetology 2021 20:168

    Content type: Original investigation

    Published on:

  43. There is a controversy over the association between obesity and the risk of renal events in patients with type 2 diabetes mellitus (T2DM). Furthermore, whether body weight (BW) loss following sodium glucose co...

    Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang and Pao-Hsien Chu

    Citation: Cardiovascular Diabetology 2021 20:167

    Content type: Original investigation

    Published on:

  44. Nesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma ne...

    Authors: Nikolaos P. E. Kadoglou, Emmanouil Korakas, Stylianos Lampropoulos, Eirini Maratou, George Kassimis, Nikolaos Patsourakos, Panagiotis Plotas, Paraskevi Moutsatsou and Vaia Lambadiari

    Citation: Cardiovascular Diabetology 2021 20:166

    Content type: Original investigation

    Published on:

  45. COVID-19 diabetic adults are at increased risk of severe forms irrespective of obesity. In patients with type-II diabetes, fat distribution is characterized by visceral and ectopic adipose tissues expansion, r...

    Authors: Franck Phan, Samia Boussouar, Olivier Lucidarme, Mohamed Zarai, Joe-Elie Salem, Nadjia Kachenoura, Khaoula Bouazizi, Etienne Charpentier, Yasmine Niati, Hasnae Bekkaoui, Zahir Amoura, Alexis Mathian, Olivier Benveniste, Patrice Cacoub, Yves Allenbach, David Saadoun…

    Citation: Cardiovascular Diabetology 2021 20:165

    Content type: Original investigation

    Published on:

  46. High-risk coronary artery plaque (HRP) is associated with increased risk of acute coronary syndrome.

    Authors: Laurits Juhl Heinsen, Gokulan Pararajasingam, Thomas Rueskov Andersen, Søren Auscher, Hussam Mahmoud Sheta, Helle Precht, Jess Lambrechtsen and Kenneth Egstrup

    Citation: Cardiovascular Diabetology 2021 20:164

    Content type: Original investigation

    Published on:

  47. Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardi...

    Authors: Job A. J. Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G. F. Cleland, Faiez Zannad and Stephane R. B. Heymans

    Citation: Cardiovascular Diabetology 2021 20:163

    Content type: Original investigation

    Published on:

  48. In a cohort study performed using primary care databases in a General Practitioners Network, Groenewegen et al. report a clear association between diabetes and incidence of the major chronic progressive heart ...

    Authors: Lucia La Sala and Antonio E. Pontiroli

    Citation: Cardiovascular Diabetology 2021 20:162

    Content type: Commentary

    Published on:

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics